Diffuse midline gliomas (DMGs) are some of the most aggressive and deadly childhood brain tumors. These cancers, which mainly ...

The poster titled “Preclinical and Translational Pharmacokinetics of GD2-SADA, a Self-Assembling and Disassembling (SADA) Bispecific Fusion Protein for Pretargeted Radioimmunotherapy (PRIT)” ...

Y-mAbs Therapeutics, Inc. has presented preclinical and translational pharmacokinetic data of their GD2-SADA bispecific fusion protein at the 2025 Society of Nuclear Medicine & Molecular Imaging ...

Financial writer recommends buying YMAB stock despite declining sales and uncertainty in radiotherapy platform, pending ...

This drops to 1 in 10, for children who relapse. For those children, their last chance is Anti-GD2 antibody therapy, said lead researcher and senior report author Associate Professor Orazio ...

《重症外伤中心》是由 Netflix 制作并推出的原创韩剧，共 8 ...

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...

Danyelza, which targets GD2-positive tumors, competes with United Therapeutics’ Unituxin and Apeiron Biologics’ Qarziba. Y-mAbs received FDA approval for its GD2 product in neuroblastoma in 2020.

We previously discovered 2 that H3K27M-mutant glioma cells express high levels of the cell-surface glycolipid GD2, and that chimeric antigen receptor (CAR) T cells engineered to target GD2 cleared ...

(RTTNews) - Y-mAbs Therapeutics, Inc. (YMAB), a commercial-stage biopharmaceutical company presented preclinical and translational pharmacokinetics or PK data of GD2-SADA at the 2025 SNMMI Mid ...